NYU Langone Transplant Institute has been recognized as the top program in New York State for both liver and kidney transplantation, based on recent national data. The institute also ranks among the fastest centers for heart and lung transplants nationwide.
Robert Montgomery, MD, DPhil, director of the NYU Langone Transplant Institute, said, “The work our institution does to serve patients in need of a lifesaving transplant is second to none. Our multidisciplinary approach to treating the whole person and ensuring they are healthy enough to thrive with their new organ shows in the quality of our outcomes.”
According to information from the Scientific Registry of Transplant Recipients, NYU Langone’s kidney transplant program not only leads New York in both quality outcomes and volume but is also ranked second nationally. In 2024, surgeons at NYU Langone performed 242 deceased donor kidney transplants and 96 living donor kidney transplants.
The liver transplant team conducted 109 deceased donor and 6 living donor adult liver transplants. Pediatric cases included 10 deceased donor and 2 living donor liver transplants, carried out in collaboration with pediatric specialists at Hassenfeld Children’s Hospital at NYU Langone. The liver transplant program also leads the Northeast in delivering deceased donor organs more quickly than other centers for both children and adults.
Both living donor kidney and liver transplant programs reported a 100 percent organ and patient survival rate after one year, which is an important measure of success. NYU Langone’s kidney program is noted as the only one nationally to perform over 70 living donor kidney transplants with a perfect one-year survival rate for organs and patients.
In heart and lung transplantation during 2024, the institute completed 77 heart transplants (including adults and children) and 76 adult lung transplants. The lung transplant program achieved the highest one-year organ survival rate in New York State and outpaced other Northeastern centers in getting organs to patients on waitlists. Heart transplant rates at NYU Langone are faster than any other program in New York City, with three-year recipient survival being the best statewide.
NYU Langone has also been identified as having the highest-volume left-ventricular assist device (LVAD) program in the Northeast by device manufacturer Abbott. This sets a benchmark for advanced heart failure care in the region.
Dr. Montgomery commented, “The growth of the LVAD program demonstrates our drive to give people a better chance at life until a new heart can be made available to them.”
At Hassenfeld Children’s Hospital at NYU Langone, pediatric liver and kidney transplant programs reported zero waitlist mortality—significantly better than national averages for these procedures. The Pediatric Heart Failure and Transplant Program also delivers new hearts to young patients more quickly than regional or national norms.
Adam Griesemer, MD, surgical director of pediatric transplant programs at Hassenfeld Children’s Hospital at NYU Langone, stated: “Transplant care is a coordinated effort where every member of our team, from surgeons to nurses to support staff, plays a critical role in giving children the chance to thrive. The true measure of our work is seeing these young patients not just survive, but flourish long after surgery.”
NYU Langone Health operates as an integrated health system known for its focus on quality care across its network. Vizient, Inc., ranked NYU Langone first among 118 comprehensive academic medical centers nationwide for four consecutive years. U.S. News & World Report recently placed four clinical specialties from NYU Langone at No. 1 nationally. The health system includes seven inpatient locations, Perlmutter Cancer Center, over 320 outpatient sites in New York and Florida, two tuition-free medical schools (in Manhattan and Long Island), as well as an extensive research division.
